Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series. Two doses are now widely recommended in some age groups; there are data …

Persistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as
cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that …

Human papillomavirus (HPV) vaccine uptake consistently lags behind that of other
adolescent vaccines. In 2017, uptake of a single HPV vaccine dose and HPV vaccine series …

Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series; a two-dose series is now recommended in some age groups and there is interest in …

Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …

Background A reduced, 2-dose schedule of human papillomavirus (HPV) vaccination has
been endorsed for preadolescent women on the basis of immunogenicity data from …

Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …

Human papillomavirus (HPV) vaccination is routinely recommended for adolescents aged
11 or 12 years but can begin at age 9. On-time HPV vaccination by the thirteenth birthday …

Clinician recommendation remains a critical factor in improving HPV vaccine uptake.
Clinicians practicing in federally qualified health centers were surveyed between October …

OBJECTIVES: We sought to prioritize interventions for increasing human papillomavirus
(HPV) vaccination coverage based on cost-effectiveness from a US state perspective to …